Related Experiment Video
Updated: Oct 8, 2026
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
Prevention of a first myocardial infarction
Insights
Preventing first heart attacks is crucial. Lipid-lowering therapies, including statins, offer benefits beyond cholesterol reduction by stabilizing arteries and preventing plaque rupture.
Area of Science:
- Cardiology
- Pharmacology
- Preventive Medicine
Background:
- Coronary heart disease (CHD) is a primary cause of death globally.
- Preventing initial coronary events through lifestyle and medication is essential.
- Atherosclerotic plaque rupture in inflamed arteries triggers thrombotic events.
Purpose of the Study:
- To highlight the multifaceted benefits of lipid-lowering therapies.
- To emphasize the role of various drug classes in plaque stabilization.
- To discuss the significance of lipoprotein subfractions in cardiovascular risk.
Main Methods:
- Analysis of event reduction trials.
- Review of pharmacologic mechanisms of action for lipid-lowering drugs.
- Examination of the role of lipoprotein subfractions, particularly small dense LDL.
Main Results:
- Lowering LDL-C is insufficient alone for plaque stabilization.
- HMG-Co-A-reductase inhibitors, fibrates, and statins provide lipid, inflammatory, rheologic, and coagulation benefits.
- Small dense LDL particles are highly atherogenic, necessitating aggressive combination therapy.
Conclusions:
- Comprehensive lipid-lowering strategies are vital for preventing first myocardial infarction.
- Understanding drug metabolism and interactions is critical for effective therapy.
- Combination therapy targeting multiple risk factors improves cardiovascular event prevention.
Abstract:
Coronary heart disease is the leading cause of morbidity and mortality in men and women in the Western world. We now have significant evidence that prevention of the first coronary event using lifestyle and pharmacologic therapies is paramount. Events are caused by inflamed arteries leading to rupture of atherosclerotic plaques that induce potentially occlusive thrombi. Analysis of event reduction trials has revealed that LDL-C lowering is only one part of the therapy needed to stabilize plaque. HMG-Co-A-reductase inhibitors, fibrates, and statins all have differing mechanisms of action that provide not only lipid but also inflammatory, rheologic, and coagulation benefits. Concentration and sizes of lipoprotein subfractions have emerged as important new tools with small dense LDL particles having more atherogenicity, which has led to an increasing use of aggressive combination therapy for prevention of first myocardial infarction. Proper use of lipid-lowering therapies requires knowledge of drug metabolism drug-drug interactions.
Related Concept Videos
01:26Coronary Artery Disease IV: Preventive Measures
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Atherosclerosis III: Management
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:14Myocarditis III: Medical Management
01:26Angina IV: Management